(Q37895805)

24 August 2017

1 reference

title

CMF revisited in the 21st century (English)

1 reference

24 August 2017

4

E P Winer

1 reference

24 August 2017

E Munzone

1

1 reference

24 August 2017

G Curigliano

series ordinal

2

1 reference

24 August 2017

H J Burstein

series ordinal

3

1 reference

24 August 2017

A Goldhirsch

series ordinal

5

1 reference

24 August 2017

publication date

29 June 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

23

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

305-311

1 reference

Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

MOPP chemotherapy for advanced Hodgkin's disease. Prognostic factors in 81 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Karnofsky memorial lecture. Conceptual and practical advances in the management of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Penicillin- and cephalosporin-resistant Streptococcus pneumoniae. Emerging treatment for an emerging problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Gr

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol I

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Prognostic markers in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Directed therapy of subtypes of triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR309

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDR309

1 reference

24 August 2017

1 reference